Is AbbVie stock a good buy?

AbbVie stock has received a consensus rating of buy. The average rating score is and is based on 31 buy ratings, 14 hold ratings, and 2 sell ratings. What was the 52-week low for AbbVie stock? The low in the last 52 weeks of AbbVie stock was 130.96. According to the current price, AbbVie is 114.73% away from the 52-week low.

What are abbv share price forecasts?

Their ABBV share price forecasts range from $140.00 to $195.00. On average, they anticipate the company's share price to reach $165.07 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

What does AbbVie do?

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

Why did AbbVie IPO?

The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size.